Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Squamous Cell Lung Cancer - Amrubicin in Advanced Squamous Cell Lung Cancer

Society for the study of previously treated squamous cell lung cancer0 个研究点目标入组 30 人开始时间: 2010年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have previously treated with chemotherapy containing amrubicin. 2) Patients with symptomatic brain metastasis. 3) Patients with massive uncontrolled pleural or pericardial effusion ,or ascites. 4) Patients with active severe infections 5) Patients with double cancer within 5 years. 6) Patients with active interstitial pneumonia recognized by chest X-ray. 7) Patients with serious drug allergic reactions. 8) Patients with active concomitant pregnancy. 9) Patients can not prevent a pregnancy. 10) Patients with cardiac infarction or unstable angina within 12 months. Patients need to recieve medications for their bad heart function. 11) Patients who have previously treated with a cumulative daunorubicin dose > 25 mg/kg, doxorubicin >500 mg/m2, epirubicin >900mg/m2, pirarubicin > 950mg/m2. 12) a serious or uncontrolled concomitant systematic disorder (active gastric or duodenal ulcer, uncontrolled diabetes mellitus, or cerebral infarction within 6 months.) 13) Conditon requiring chronic systematic administration of corticosteroids. 14) Inappropriate patients for this study judged by the physicians

发起方

Society for the study of previously treated squamous cell lung cancer